Psychedelics as Therapeutic for Substance Use Disorders - Emerging Treatment Update-Presentation and Q&A

Video Transcription

Video Summary

The video transcript is a webinar discussing the potential therapeutic use of psychedelics, such as LSD, psilocybin, ketamine, and ibogaine, in the treatment of substance use disorders. Various studies and clinical trials are mentioned, including the use of LSD for reducing opiate dependence and psilocybin for reducing tobacco addiction and alcohol consumption. Ketamine is highlighted for its potential in preventing relapse and promoting abstinence in alcohol use disorder. The safety concerns of ibogaine are mentioned, along with its potential benefits for opiate use disorder. The use of MDMA for alcohol use disorder and its potential rescheduling for PTSD are briefly mentioned. The mechanisms of action of psychedelics, such as receptor interactions and neuroplasticity, are discussed. Safety concerns and harm reduction practices are addressed, and additional resources for further information are provided. Audience questions cover topics such as the use of psychedelics in patients with dissociative episodes, the effects on patients taking SSRIs, and the potential use in treatment-resistant cases and patients with bipolar or schizophrenia.<br /><br />The first summary describes a webinar presented by Benjamin Buchholz on psychedelics for addiction treatment, while the second summary is of a video by Dr. Sagga discussing various psychedelics and their potential therapeutic uses in substance use disorder treatment.

Keywords

webinar

therapeutic use

psychedelics

LSD

psilocybin

ketamine

ibogaine

substance use disorders

clinical trials

opiate dependence

alcohol consumption

MDMA